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A review is made of the late diagnosis of human immunodeficiency virus (HIV) infection, a subject of growing 
interest in public health. It has been estimated that in Europe 30% of all HIV-infected people are unaware of their 
seropositive condition, and this in turn is associated with a poorer long-term disease prognosis and an increased 
risk of transmission to other individuals. The role of the dental surgeon in this context could be of great impor-
tance, since there are many oral lesions that can suggest the existence of underlying infection. The study also 
addresses the controversial subject of rapid HIV testing, and whether these tests should be performed on a routine 
basis in the dental clinic, or whether it is preferable to refer the patient to a specialized center.
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The late diagnosis of HIV infection in Spain; 
magnitude, risk factors and implications
The natural course of HIV infection has changed no-
toriously as a result of the introduction of combina-
tion or highly active antiretroviral therapy (HAART), 
which began to be administered in Spain in 1997. Such 
treatment has led to a drastic reduction in mortality as-
sociated to the acquired immunodeficiency syndrome 
(AIDS), and to increased survival among HIV-infected 
individuals HIV (1). In the year 2009, the HAART re-
sponse rate was very high, affording sufficient host im-
mune recovery to allow the control of opportunistic in-
fections, thanks to the introduction of increasingly well 
tolerated and simpler treatments such as the combina-
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tion of several drug substances in a single tablet (2).
However, despite initiatives to promote the early di-
agnosis of HIV infection in Europe in the last decade, 
studies suggest that there is still a significant proportion 
of individuals who are not aware of their seropositive 
condition (3). In Europe, it has been estimated that 30% 
of all HIV-positive subjects are unaware that they have 
been infected (4), and that these individuals could be 
responsible for almost 60% of all new infections (5). 
At present, most cases of HIV infection in Spain are 
found in heterosexuals and male homosexuals, and to 
a lesser degree in intravenous drug abusers. Further-
more, at least 30% of all new diagnoses correspond to 
individuals born outside the country (2,6). In relation to 
the late diagnosis of HIV infection in Spain (CD4+ lym-
phocyte count < 350 cells/mm3), most cases correspond 
to males over 50 years of age, intravenous drug abusers 
or heterosexuals, and people born outside the country 
(6). Based on this definition, and analyzing the data of 
the adult seropositive cohort of the AIDS Investigation 
Network (Red de Investigación en SIDA, CoRIS), the 
late diagnosis rate is about 48%, and affects mainly 
males over 50 years of age, heterosexuals, and people 
born outside of Spain (7).
These observations have important clinical and public 
health implications. Late diagnosis is clearly associated 
to a greater risk of progression towards AIDS and to in-
creased morbidity and mortality. In addition, HAART 
toxicity increases in the presence of lower CD4+ lym-
phocyte counts at the start of therapy. Lastly, and no less 
importantly, a delayed diagnosis implies a greater risk 
of inadvertent HIV transmission (5,8).
Thus, a delay in diagnosing the disease is one of the 
main challenges of the HIV epidemic today. The defini-
tion of “late diagnosis” has been the subject of debate 
and controversy, though in Europe the term is taken 
to imply patients who at the time of diagnosis present 
CD4+ lymphocyte counts of < 350 cells/mm3, or show 
clinical manifestations of AIDS (9).
Strategies for reducing the late diagnosis of HIV 
infection: the role of the dental surgeon
Traditionally, HIV testing has been offered to people 
and population groups at risk of becoming infected with 
the disease, such as intravenous drug abusers, male ho-
mosexuals or immigrants from countries in which the 
infection is very prevalent. Some studies indicate that 
only one-third of all patients seen in the healthcare serv-
ices with suggestive clinical processes (clinical indica-
tors) or with risk behavior or risk factors are subjected 
to serological testing for HIV (10). In addition, between 
10-25% of all seropositive individuals do not refer ante-
cedents of risk behavior (11).
A number of initiatives have been launched in recent 
years to improve the diagnosis of HIV infection. In the 
year 2006, the United States Centers for Disease Con-
trol (CDC) published recommendations for increasing 
the early diagnosis of the disease and for expanding the 
role of the healthcare professionals in reducing the high 
rates of late diagnosis (12). These guidelines suggest that 
healthcare professionals should recommend HIV test-
ing in all people between 13-64 years of age, as part of 
routine healthcare practice. In order to eliminate poten-
tial barriers against HIV testing, the CDC also proposed 
obviating the need for a “counseling pretest” and signed 
informed consent form specific for HIV testing – without 
this meaning that the test is no longer voluntary.
Posteriorly, the WHO/UNAIDS (13), some national 
health agencies (14), and many medical societies (15), 
unanimously recommended the routine prescription of 
HIV tests in patients with clinical markers suggestive of 
infection (i.e., with disorders “indicative” of underlying 
HIV infection), or with individual behavioral or other 
risk factors.
Recently, the European Center for Disease Prevention 
and Control (ECDC), through its website (www.ecdc.
Europe.eu), has published a series of guidelines on HIV 
testing in Europe (16).
The strategy adopted by the CDC is to perform general-
ized HIV testing of all people accessing the healthcare 
system for any reason, and a number of studies have 
established that this measure would be cost-effective in 
regions where the prevalence of undiagnosed HIV in-
fection is over 0.1% (17). Cost-efficacy studies are being 
carried out in the United Kingdom, and this strategy 
has also been adopted in France with the purpose of re-
ducing delays in diagnosis (14,18). In Spain a study has 
been made in Primary Care Centers of the Community 
of Madrid, in the context of an infectious diseases se-
rovigilance survey – the observed prevalence of hidden 
(i.e., undiagnosed) HIV infection being about 0.35% 
(95%CI 0.13-0.57%)(19).
In any case, it is important to distinguish between HIV 
testing offered to people with known risk behaviors or 
as part of an antenatal screening program in pregnant 
women and a diagnosis derived from the actual pres-
ence of clinical signs or symptoms of underlying HIV 
infection. It is in this latter scenario where dental sur-
geons as well as other healthcare professionals may play 
an important role. Many clinical and behavioral indica-
tors of underlying HIV infection (Tables 1 and 2) can be 
used by dental professionals with the purpose of refer-
ring a patient for HIV testing or of performing rapid 
HIV testing in the dental clinic itself (2).
Specific platforms have been created both in Europe 
(“HIV in Europe”) and in Spain (“HIV in Spain 2009 
and 2010”) to promote the early diagnosis of HIV, with 
the support of the health authorities and the political and 
social leaders. Specifically, in Spain these programs for 
the early detection of HIV infection are supported by 
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Table 1. Opportunistic infections or neoplasms suggestive of AIDS in 
which HIV testing ALWAYS must be recommended (2).
In red: diseases that can be identified in a dental clinic; CMV: cytomega-
lovirus; HSV: herpes simplex virus; HIV: human immunodeficiency 
virus.
Table 2. Situations in which HIV screening is recommended (2).
(*) The prevalence in Spain is <1%, but the potential benefit for the new-
born infant justifies the recommendation of systematic HIV screening.
the Secretariat of the National AIDS Plan (2), and are 
targeted to all potentially implicated healthcare profes-
sionals – including dental surgeons. 
Among the main conclusions drawn by the members 
of the “HIV in Europe” platform held in 2007, mention 
should be made of the following recommendations for 
HIV screening in Europe:
(3)All healthcare professionals should be aware of the 
need to perform HIV tests in more individuals, and 
should be familiarized with the range of lesions in 
which the prevalence of underlying HIV infection justi-
fies patient referral for testing.
(4)Certain healthcare professionals such as general prac-
titioners, dentists, dermatologists, specialists in sexually 
transmitted diseases, gynecologists and emergency care 
physicians should be specific targets for this type of initi-
ative, since they are more likely to be the first to encoun-
ter HIV-infected patients with comorbidities (8).
Furthermore, in the context of dental practice, the com-
mittee of the “HIV in Europe” platform considers that 
as long as data are pending on the prevalence of HIV 
1.- Tracheal, bronchial or pulmonary candidiasis
2.- Esophageal candidiasis
3.- Invasive cervical carcinoma
4.- Disseminated coccidiomycosis
5.- Extrapulmonary cryptococcosis
6.- Cryptosporidiasis (with diarrhea for more than one 
month)
7.- CMV infection
8.- Retinitis due to CMV
9.- Encephalopathy due to HIV
10.- HSV infection (causing mucocutaneous ulceration 
for over one month)
11.- Disseminated histoplasmosis
12.- Chronic isosporidiasis (over one month)
13.- Kaposi’s sarcoma
14.- Burkitt lymphoma or equivalent
15.- Immunoblastic lymphoma
16.- Primary cerebral lymphoma
17.- Infection due to M. avium-intracellulare or M. 
kansasii (disseminated or extrapulmonary)
18.- Lung tuberculosis
19.- Extrapulmonary or disseminated tuberculosis
20.- Infection due to other mycobacteria (disseminated or 
extrapulmonary)
21.- Pneumocystis jiroveci pneumonia
22.- Recurrent pneumonia
23.- Progressive multifocal leukoencephalopathy
24.- Recurrent sepsis caused by Salmonella species other 
than S. typhi
25.- Cerebral toxoplasmosis 
26.- Cachexia syndrome due to HIV
1.- Any sexually transmitted infectious disease (syphi-
lis, gonococcus, Chlamydia, HPV, etc.)
2.- Sexual risk practices or sexual intercourse with 
HIV-1 infected individuals
3.- Influenza syndrome with rash and/or adenopathies
4.- Long-evolving fever of unknown origin
5.- Onychomycosis
6.- Recurrent herpes simplex
7.- Herpes zoster or varicella
8.- Seborrheic eczema
9.- Psoriasis
10.- Oral candidiasis (PMC, EC, AC)
11.- Oral hairy leukoplakia
12.- NG, NP or LGE
12.- Hepatitis C
13.- Hepatitis B (HBsAg+)
14.- Leukopenia, lymphopenia, thrombopenia, anemia 
(of no apparent cause)
15.- Elevated erythrocyte sedimentation rate
16.- Chronic or nonspecific diarrhea / Rapid weight loss
17.- Hodgkin lymphoma, Castleman’s disease
18.- Leishmaniasis
19.- Community-acquired pneumonia (prolonged, atypical 
or recurrent)
20.- Respiratory infection due to Rhodococcus equi
21.- Dysphagia due to ulcerated lesions
22.- Infectious mononucleosis
23.- Patients with cervical or anal cancer
23.- All pregnant women*
infection among patients with such comorbidities, the 
presence of oral manifestations suggestive of underly-
ing HIV infection is indicative of the need to perform 
diagnostic tests (8).
In addition, it must be taken into account that adults 
over 20 years of age tend to visit their dentist more often 
than their physician (20); as a result, dental surgeons 
may have an important opportunity to detect underly-
ing HIV infection (21).
Orofacial clinical indicators suggestive of HIV 
infection 
From the start of the HIV epidemic, the oral cavity has 
played an important role in monitoring the progression 
of HIV infection through the appearance of specific le-
sions – fundamentally oral candidiasis (OC) and oral 
hairy leukoplakia (OHL), which have been closely cor-
related to low CD4+ lymphocyte counts and high plas-
ma viral loads (22-24). Thus, it has been estimated that 
over 90% of all AIDS patients present one or more oral 
manifestations during the course of the disease, and 
these manifestations are moreover often the first sign of 
immune depression (25).
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On the other hand, the prevalence of specific lesions 
such as OC, OHL and Kaposi’s sarcoma (KS) is dimin-
ished in patients subjected to highly active antiretrovi-
ral therapy (HAART)(26,27), while other oral lesions 
such as papillomas and salivary gland disorders are in-
creased in such individuals - thus suggesting that they 
may form part of an immune reconstitution syndrome 
(IRS), secondary to the start of HAART (22,28).
In London in 1992 the World Health Organization 
(WHO) and the EC -Clearinghouse developed a classifi-
cation based on the prevalence of oral manifestations in 
HIV-positive patients. Three groups were established, 
and in Group 1, corresponding to oral lesions common-
ly associated with HIV infection, the following condi-
tions are enumerated: pseudomembranous candidiasis 
(PMC); erythematous candidiasis (EC); angle cheilitis 
(AC); oral hairy leukoplakia (OHL); necrotizing gingi-
vitis (NG); necrotizing periodontitis (NP); linear gingi-
val erythema (LGE); Kaposi’s sarcoma (KS); and non-
Hodgkin lymphoma (NHL)(29).
Recently, the Oral HIV/AIDS Research Alliance 
(OHARA), which forms part of the AIDS Clinical Tri-
als Group (ACTG) and was created in 2006 to inves-
tigate all orofacial aspects of HIV infection, has pub-
lished an update on the definitions of the oral manifes-
tations of HIV-positive patients. The update is based 
on the 1992 classification of the EC – Clearinghouse, 
and contemplates the clinical descriptors of the Group 
1 oral lesions (1992) plus other conditions such as oral 
papilloma, labial herpes, recurrent intraoral herpes and 
recurrent aphthous stomatitis (since these disorders 
are very prevalent in such patients). In addition, it ad-
dresses the symptoms of the patients and the duration of 
the disease, if known. On the other hand, lesions such 
as “nonspecific ulcerations” (NOS) have been merged 
with “necrotizing ulcerative stomatitis” in order to fa-
cilitate the diagnosis for non-expert professionals. In 
the same way, NG and NP have been merged, since they 
cannot be distinguished by visual inspection if X-rays 
and periodontal probing are not available. Another pro-
posed change is addition of the definition of oral squa-
mous cell carcinoma (OSCC) associated to HIV, since 
there is evidence of an increased risk of OSCC in HIV-
positive individuals versus the general population. On 
the other hand, division of the section “Salivary gland 
disease” into two separate categories - “salivary hypo-
function” and “salivary gland swelling” - has been pro-
posed, since they may manifest independently in one 
same patient (22).
A number of studies have reported that Group 1 oral 
lesions, alone or in combination, could be used as diag-
nostic markers in the screening of patients suspected to 
be seropositive for HIV (30,31), particularly in centers 
with limited resources, or where patients are reluctant 
to undergo HIV testing (32).
In 1998, Robinson et al. (32) evaluated the usefulness of 
oral lesions as predictors of underlying HIV infection 
in populations with different prevalences of the infec-
tion. In the general population, where the prevalence of 
HIV infection is low, the clinical diagnosis of Group 
1 oral lesions alone was seen to be a poor predictor of 
HIV infection, with many false positive results. How-
ever, the positive predictive value (PPV) increased on 
using information from the medical records, such as for 
example infection risk behavior. Thus, only 2.6% of the 
individuals in England and Wales presenting oral le-
sions similar to OHL would have HIV infection, but in 
the case of a homosexual male the PPV would increase 
to 57.4%, and to 73.8% in the city of London (32).
In 2008, Bhayat et al. (30) carried out another study 
attempting to predict HIV infection among dental pa-
tients who were unaware of their seropositivity. They 
found that if a patient presented NG, the probability of 
HIV infection was 40 times greater than in the absence 
of NG (30).
This same group recently carried out a study to deter-
mine the prevalence of HIV infection and of Group 1 
oral lesions among adults seen in a Primary Care Center 
in South Africa. They examined a total of 522 patients, 
and the prevalence of HIV infection was found to be 
40%. Of these patients, 53% presented some Group 
1 oral lesion – PMC and EC being the most common 
findings. The Odds Ratio (OR) of having HIV infec-
tion in the presence of OHL was 38, versus 78 in the 
case of multiple PMC plus OHL lesions. In patients with 
combinations of multiple oral lesions, the mean positive 
predictive value (PPV) and negative predictive value 
(NPV) was 91.7% and 61.2%, respectively. The authors 
therefore concluded that Group 1 oral lesions alone or 
in multiple combinations can be reliably used as HIV 
screening tools, particularly in centers with limited re-
sources, or where testing is little used or is very expen-
sive (33). In addition, they pointed out that the useful-
ness of these Group 1 oral lesions is limited by clinician 
skill in being able to recognize and correctly diagnose 
them. Thus, correct clinician training in the diagnosis 
of these lesions is very important, since it may increase 
the number of patients referred for HIV screening and 
avoid a late diagnosis of this infection.
Based on the above data and on the review of the litera-
ture, table 3 proposes a series of orofacial manifesta-
tions suggestive of underlying HIV infection, including 
not only the commented Group 1 oral lesions but also 
the suggestions of the OHARA and those oral manifes-
tations of the most common sexually transmitted infec-
tions which we feel to justify the decision of the dental 
surgeon to refer the patient for HIV testing (Table 3)
(Figs. 1,2). 
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Oral candidiasis (PMC; EC; AC or multifocal candidiasis *)
Oral hairy leukoplakia
Periodontal lesions (LGE; NG; NP)
Kaposi’s sarcoma
Non-Hodgkin lymphoma
Oral lesions suggestive of sexually transmitted infection (syphilitic 
chancre, gonococcal NG, lesions due to HPV such as papillomas or 
condylomas, etc.)
Secondary tuberculosis oral lesions (granulomatous ulcers)
Xerostomia (salivary hypofunction)
Salivary gland swelling
Long-evolving HSV lesions (> 1 month)(including labial herpes and 
recurrent intraoral herpes)
Aphthous lesions refractory to conventional treatment
Option 1: Refer patient for HIV screening + 
Counseling:




Option 2: Rapid HIV test with Oraquick 
Advance® + Counseling
(*) Assess multifocal character of lesions due to Candida, as well as 
the presence of different oral lesions in one same patient. The HIV 
predictive value increases considerably if there is moreover also 
risk behavior.
 
Table 3. HIV screening proposal based on orofacial manifestations suggestive of underlying HIV infection.
PMC: pseudomembranous candidiasis; EC: erythematous candidiasis; AC: angle cheilitis; LGE: linear gingival erythema; NG: necrotizing gingivitis; 
VHS: herpes simplex virus; HPV: human papillomavirus; NGO: non-government organization; NP: necrotizing periodontitis.
Fig. 1. Oral lesions found to be highly prevalent in HIV-positive pa-
tients. A) Pseudomembranous candidiasis (PMC) of the tongue and 
bilateral angle cheilitis. B) PMC of the palate in the same patient as 
before (multifocal candidiasis). C) Erythematous candidiasis (EC). 
D) Necrotizing gingivitis. E) Oral hairy leukoplakia (right lateral 
margin of the tongue). F) Oral hairy leukoplakia in the same patient 
(left lateral margin).
Fig. 2. Other oral lesions that may be found in HIV-positive patients. 
A) Human papillomavirus (HPV) lesion. B) Lesion of the lateral 
margin of the tongue due to recurrent aphthous stomatitis. C) Plas-
mablastic lymphoma of the palate. D) Secondary oral tuberculosis 
lesion in an undiagnosed HIV-positive patient. E) Kaposi’s sarcoma 
of the gums. F) Oral condyloma lesion of the palate.
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Rapid HIV testing in dental practice. Controver-
sial aspects
The CDC recommends that in order to improve preven-
tion and the results of combination antiretroviral therapy 
(HAART), and to reduce HIV transmission, the places 
where testing can be made should be diversified beyond 
the usual settings – this in some instances including the 
use of rapid tests (34). 
Routine HIV diagnostic tests are predominantly carried 
out using blood samples, and the results are obtained 
within 10-14 days. Almost 30% of all tested individuals 
fail to report to pick up their test results (35).
A rapid HIV detection test known as the Oraquick Ad-
vance® (Orasure Technologies, Bethelem, PA, USA) 
has been approved by the United States FDA, and can 
yield results in 20 minutes. This test detects antibodies 
against HIV-1 and HIV-2 in gingival crevicular fluid 
(GCF)(transudate), in whole blood from a finger prick 
sample, in whole blood drawn from a vein, and in plasma 
samples, based on ELISA technology (21). The test can 
be used outside the traditional clinical office setting in 
the United States, provided the clinician holds a special 
certificate from the CLIA (Clinical Laboratory Improve-
ment Amendments) and is trained in performing the test 
and in interpreting the results (35). As a result, this test 
could easily be used in a dental clinic using GCF sam-
ples. In Spain a number of non-government organizations 
(NGOs) have been using the test for several years.
The mentioned rapid test was evaluated by Debattista 
et al. (2007) and by Wesolowski et al. (2006), yielding 
a mean specificity and sensitivity of 100% and 98.3%, 
respectively, and having been used in screening studies 
in a number of countries (36,37). The reviewed studies 
that have used this diagnostic kit have reported specifi-
city values of between 99-99.87%, and sensitivity values 
in the range of 96-100% (38,39).
False positive readings are rare, particularly when sam-
pling has been correctly performed. In this context, the 
sample consists of crevicular fluid (not saliva), which is 
produced within the gingival sulcus between the tooth 
and the gums. It has been estimated that there may be 
1-2 false positive readings per 1000 tests. If incorrect 
sampling is discarded, such false positive results may be 
associated to the presence of antibodies in the GCF tar-
geted to other viral infections such as Epstein-Barr virus 
or hepatitis A or B. Negative results should be regarded 
as definitive (35). It is important to emphasize that a point 
in favor of such testing is the fact that the dental surgeon 
precisely knows the origin and the composition of the 
crevicular fluid sample. This greatly facilitates correct 
learning of the technique, eliminating errors that could 
occur with other professionals by confusing crevicular 
fluid with normal saliva – the origin and composition of 
which is different (21). However, in addition to this as-
pect, it must be taken into account that any HIV test must 
be accompanied by patient information and consent both 
before and after the test. 
It is here where the discrepancies and controversial is-
sues appear. In effect, in a country such as Spain, where 
almost all dental care is private, the following questions 
could be raised, as has already been done by other au-
thors in the United States (21):
- Would dental surgeons have the ethical and profession-
al responsibility to offer rapid HIV tests to all patients, 
considering the public health problem posed by the fact 
that many HIV-infected individuals are unaware of their 
seropositivity?
- Do dental surgeons have the training needed to perform 
the rapid diagnostic test and interpret its results?
- Do dental surgeons have to offer patients pre-test coun-
seling and/or information?
- Should they refer the patient to the public healthcare 
system for HIV testing in the presence of the abovemen-
tioned clinical and behavioral indicators?
In relation to this subject, mention should be made of 
the many barriers facing rapid HIV testing in the dental 
clinic, and which could be extrapolated to the situation 
found in our country (40): (i) shortcomings in terms of 
knowledge and adequate training in rapid HIV testing 
among dental professionals; (ii) fear, concern or inexpe-
rience in giving bad news to patients; (iii) a lack of inter-
est in such testing among dental professionals; (iv) the 
perception that HIV testing is not a competence of the 
dental surgeon; (v) reluctance on the part of the patient to 
undergo such a test in a dental clinic; and (vi) economical 
and time issues.
On the other hand, it must be taken into account that dental 
professionals in Spain work at different levels – fundamen-
tally in private practice, but also in Primary Care (PC), 
University academic centers, and increasingly also in al-
ready established Hospital Departments of Stomatology 
and existing and/or future Hospital Odontology Units. 
This situation raises the hypothesis that rapid HIV test-
ing would be best performed by dental professionals 
within the public healthcare system, particularly dentists 
in Primary Care, after receiving adequate specific train-
ing in the technique and in the pre-test information given 
to patients. Testing in this scenario would be justified by 
the fact that many patients visit a dentist more often than 
a physician. Another aspect to be considered is whether 
it would be more advisable to include these aspects and 
issues in the university training of future dental surgeons 
– most of which will ultimately work in private practice. 
In this context, the data obtained by Patton et al. in 2002 in 
American universities are not very encouraging, since only 
33% of the Dental Schools were found to include the legal 
aspects of HIV screening in their curricula, and only 15% 
informed their students of when to refer a patient for HIV 
testing. Moreover, 63% of the surveyed Dental Schools did 
not offer HIV testing to their own patients (40).
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Considering the above and based on the existing infor-
mation, we consider that the dental surgeon, in the same 
way as in screening for oral cancer, could be a key ele-
ment in the early diagnosis of patients with underlying 
HIV infection. Since the oral cavity is very accessible, 
and many patients visit their dentist more often than their 
personal physician, we feel that detection of the oral in-
dicators proposed in Table 3 would be strongly sugges-
tive of the need to refer the patient to Primary Care, to a 
center specialized in sexually transmitted diseases, or to 
a hospital center for due confirmation of HIV infection 
and patient counseling. 
In the not too distant future, dental professionals in 
our country might adopt a more active role in the 
early detection of HIV infection – though this will 
require all aspects related to the rapid test to become 
incorporated as part of the global competences of the 
dentist, in the same way as performing a biopsy when 
oral cancer is suspected. In this sense the study plans 
of our Dental Schools will have to be updated, incor-
porating this new function to further implicate dental 
surgeons in public health matters. Until then, a good 
option would be to inform and enhance awareness 
among the dental professionals of the problem posed 
by late or delayed diagnosis in HIV infection and its 
healthcare consequences, through the Professional 
Dental Colleges network (2), the General Council, 
Dental Schools, Scientific Societies, journals and 
webpages of our discipline. Such information should 
be conveyed not only to dental professionals but also 
to patients who thus may begin to regard their “usual 
dentist” as a healthcare professional concerned about 
their general health – not only their dental health.
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